Christina (Tina) P: Help Advance Research and Support Patients with Antiphospholipid Syndrome
Christina (Tina) P., CEO and Co-Founder of APS Foundation of America, shared on LinkedIn:
”Antiphospholipid Syndrome (APS) is an autoimmune disorder where your immune system mistakenly attacks proteins in your blood, making it clot more easily.
This can lead to serious health problems like blood clots in veins and arteries (deep vein thrombosis, pulmonary embolism), strokes, heart attacks, and repeated miscarriages or stillbirths.
It can affect anyone, though it’s more common in women and often diagnosed between ages 20 and 40.
Here’s why donating to the APS Foundation of America, Inc. is so important:
The APS Foundation of America is dedicated to supporting both adult and pediatric research into APS. In 2025, they awarded three $10,000 microgrants to research teams and $10,000 to ICAPA. They also aim to set aside 10% of donations for future research funding.
Education and Awareness: They provide vital information and education about APS to patients, their families, and the general community.
This includes information on diagnosis, symptoms, treatment, and coping.
They also work to raise national awareness for APS, which is the leading cause of stroke in young people and a significant factor in recurrent miscarriages.
The APS Foundation of America offers support and resources for those living with APS, including a network of doctors familiar with the condition and an online forum for communication with other patients.
They advocate for earlier diagnosis and better patient care.
Founded in 2005, the APS Foundation of America is a volunteer-run 501(c)(3) public charity.
They strive to keep administrative costs low, with many members being patients themselves.
They also aim for transparency, with a Charity Navigator score of 98% for accountability and finance.
Your donations help the APS Foundation of America continue its crucial work in fighting this often-misunderstood illness, advancing research, and supporting those affected.
Corporate Donations message us.”
Stay updated with Hemostasis Today.
-
Mar 16, 2026, 18:20Ahmed Koriesh: Stroke Prevention in the New 2026 ACC/AHA Dyslipidemia Guideline
-
Mar 16, 2026, 18:13Nameer Ascandar: Outcomes After GI Bleeding in Patients with Rheumatoid Arthritis and AF on Long-Term Oral Anticoagulation
-
Mar 16, 2026, 17:42Mohamed Sherif Salem: Turning 2026 KDIGO Complexity into Bedside Clarity
-
Mar 16, 2026, 17:39Julie Cardoso: What Happens to Venous Valves When a Blood Clot Forms?
-
Mar 16, 2026, 17:38Nasir Jamal: Blood Transfusion Criteria and Hemodialysis Thresholds in ESRD Patients
-
Mar 16, 2026, 17:37Octavio Cosín Sales: Understanding the Influence of Systemic Factors on Chronic Venous Insufficiency
-
Mar 16, 2026, 17:35Shiny K. Kajal: From Simple Calcium Chelation to Full-Blown Red Cell Metabolic Engineering
-
Mar 16, 2026, 17:12Cold-Stored vs Room-Temperature Platelets in Trauma-Induced Coagulopathy – JTH
-
Mar 16, 2026, 17:10Arturo Cesaro: First Meta-Analysis on the Vascular Protective Role of Semaglutide in PAD